EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of advanced pancreatic cancer patients with opioid growth factor



Treatment of advanced pancreatic cancer patients with opioid growth factor



American Journal of Gastroenterology 95(9): 2471-2472, September




(PDF same-day service: $19.90)

Accession: 035980871

Download citation: RISBibTeXText

DOI: 10.1016/s0002-9270(00)01358-7



Related references

Treatment of advanced pancreatic cancer with Opioid Growth Factor Phase I. Gastroenterology 118(4 Suppl 2 Part 1): AGA A647, April, 2000

Treatment of advanced pancreatic cancer with opioid growth factor: phase I. Anti-Cancer Drugs 15(3): 203-209, 2004

Opioid growth factor improves clinical benefit and survival in patients with advanced pancreatic cancer. Open Access Journal of Clinical Trials 2010(2): 37-48, 2010

Safety and toxicity of opioid growth factor in patients with advanced pancreatic cancer A phase I study. International Journal of Molecular Medicine 12(Supplement 1): S34, 2003

Opioid growth factor and the treatment of human pancreatic cancer: a review. World Journal of Gastroenterology 20(9): 2218-2223, 2015

Elevated levels of opioid growth factor in the plasma of patients with pancreatic cancer. Pancreas 21(2): 158-164, 2000

Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer. Experimental Biology and Medicine 238(5): 579-587, 2013

Efficacy and safety profile of combining agents against epidermal growth factor receptor or vascular endothelium growth factor receptor with gemcitabine-based chemotherapy in patients with advanced pancreatic cancer: a meta-analysis. Pancreatology 13(4): 415-422, 2014

Anti-epidermal growth factor receptor treatment strategies in advanced pancreatic cancer: success or failure?. Journal of Clinical Oncology 29(3): E70-1; Author Reply E72-3, 2011

Impact of targeting transforming growth factor β-2 with antisense OT-101 on the cytokine and chemokine profile in patients with advanced pancreatic cancer. Oncotargets and Therapy 11: 2779-2796, 2018

New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways. Oncologist 13(3): 289-298, 2008

Epidermal growth factor receptor-targeted treatment strategies in advanced pancreatic cancer Is K-RAS mutational testing ready for prime time?. memo - Magazine of European Medical Oncology 4(4): 257-259, 2011

Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine. Clinical Cancer Research 14(3): 840-846, 2008

Enhanced growth inhibition of human pancreatic cancer cells by opioid growth factor and gemcitabine. FASEB Journal 18(4-5): Abst 649 6, 2004

Human pancreatic cancer transplanted into nude mice is growth inhibited by opioid growth factor. FASEB Journal 11(3): A542, 1997